Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06814717 | A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns | PHASE2 | RECRUITING | 6 | — | — | May 12, 2025 | Nov 1, 2026 | Feb 18, 2026 | 1 | United States |
Clinical safety labs will be collected
| Arm | Type | Description |
|---|---|---|
| Open-label | EXPERIMENTAL | Six adult male or female subjects will receive a single administration of 0.01mg/kg of cP12. |
| Name | Type | Description |
|---|---|---|
| cP12 | DRUG | cP12 is a novel fibronectin derived, 14-mer peptide |
Inclusion Criteria: * BMI between 18 kg/m2 (inclusive) and body weight \>/=50kg * TBSA thermal burns up to and including 10%. The selected burn must be superficial (epidermal), superficial partial-thickness, or deep partial-thickness * Able to be infused with cP12 within 2 to 24 hours post burn * A...